BRIEF published on 04/03/2025 at 13:24, 1 year ago Innate Pharma participates in the Stifel 2025 Virtual Targeted Oncology Forum Euronext Paris Oncology Immunotherapy Innate Pharma Virtual Forum
BRIEF published on 04/03/2025 at 13:18, 1 year ago Innate Pharma to Engage in Stifel 2025 Virtual Oncology Forum Biotechnology Immunotherapy Virtual Event Innate Pharma Oncology Forum 2025
PRESS RELEASE published on 04/03/2025 at 13:13, 1 year ago INSIDE INFORMATION / OTHER NEWS RELEASES Innate Pharma to participate in 2025 Stifel Virtual Targeted Oncology Forum. Executive team presenting and hosting 1x1 meetings. Focus on innovative cancer immunotherapies Cancer Innate Pharma Immunothérapies Stifel Targeted Oncology Forum
PRESS RELEASE published on 03/28/2025 at 14:37, 1 year 1 month ago Annual financial and audit reports / Annual financial report
BRIEF published on 03/20/2025 at 07:05, 1 year 1 month ago Innate Pharma Announces 2024 Financial Results Conference Financial Results Conference Call Stock Market Listing Cancer Immunotherapy Innate Pharma
PRESS RELEASE published on 03/20/2025 at 07:00, 1 year 1 month ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 1 year 2 months ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 2 months ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 1 year 3 months ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 3 months ago Inside Information / Other news releases Innate Pharma announces first patient dosed in Phase 1 study of Nectin-4 targeting Antibody Drug IPH4502 in advanced solid tumors. Innovative ADC for multiple cancer types Innate Pharma Phase 1 Study IPH4502 Topoisomerase I Inhibitor Antibody Drug Conjugate
Published on 05/02/2026 at 21:00, 10 hours 14 minutes ago GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 5 hours ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 6 hours ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 7 hours ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 7 hours ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/03/2026 at 04:45, 2 hours 29 minutes ago GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 15 hours 39 minutes ago Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 05/01/2026 at 19:23, 1 day 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/30/2026 at 20:00, 2 days 11 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 2 days 11 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 2 days 12 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 2 days 13 hours ago Minutes of the Combined General Meeting held on April 30, 2026
